MARKET

MDCX

MDCX

Medicus Pharma Ltd
NASDAQ
0.4066
-0.0434
-9.64%
After Hours: 0.3997 -0.0069 -1.70% 16:15 03/30 EDT
OPEN
0.4400
PREV CLOSE
0.4500
HIGH
0.4400
LOW
0.3914
VOLUME
1.45M
TURNOVER
--
52 WEEK HIGH
8.94
52 WEEK LOW
0.3700
MARKET CAP
16.00M
P/E (TTM)
-0.2061
1D
5D
1M
3M
1Y
5Y
1D
Medicus Pharma’s SkinJect Phase 2 Data Validated by KOL With 80% Response Rate
TipRanks · 14h ago
Medicus Pharma’s SkinJect Data Earns KOL Validation With 80% Response in Phase 2
TipRanks · 14h ago
Medicus Pharma reports principal investigator validation of Phase 2 data
TipRanks · 16h ago
Medicus reports KOL validates SkinJect Phase 2 data showing 80% response rate
Reuters · 18h ago
MEDICUS PHARMA REPORTS KOL VALIDATION OF SKINJECT PHASE 2 DATA OF 80% OVERALL RESPONSE RATE
Reuters · 18h ago
Weekly Report: what happened at MDCX last week (0323-0327)?
Weekly Report · 19h ago
Medicus Pharma Highlights Strong SkinJect Phase 2 Results and AI-Driven Development Plan
TipRanks · 4d ago
Medicus Pharma reports 80% ORR in Phase 2 SkinJect 200µg cohort at Day 57; FY2025 cash and cash equivalents fall to $9 million at year-end
Reuters · 4d ago
More
About MDCX
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.

Webull offers Medicus Pharma Ltd stock information, including NASDAQ: MDCX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDCX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDCX stock methods without spending real money on the virtual paper trading platform.